Use of Tedizolid for the Treatment of Staphylococcus aureus Bacteremia – An off Labelled Indication

International Journal of Medical and Pharmaceutical Case Reports

View Publication Info
 
 
Field Value
 
Title Use of Tedizolid for the Treatment of Staphylococcus aureus Bacteremia – An off Labelled Indication
 
Creator Loo, L. W.
Kwa, Andrea L.
Low, Jenny G.
Chien, Jaime
 
Description Aims: We aim to share our experience in the successful use of tedizolid for the treatment of Staphylococcus aureus bacteremia in two of our patients.
Presentation of Cases: Our first patient had methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. The MRSA isolated was sensitive to linezolid and vancomycin (MIC=2), resistant to daptomycin (MIC=2). In view of the documented drug allergy to ceftriaxone and drug interaction with daptomycin, the patient was initially initiated on intravenous vancomycin but developed a breakthrough fever with rising inflammatory markers. However, upon initiation of tedizolid, fever lysed and the patient improved clinically.
Our second patient has end–stage renal failure on hemodialysis. The patient has methicillin-susceptible Staphylococcus aureus (MSSA) catheter-related bloodstream infection. The MSSA isolated was sensitive to vancomycin (MIC=2) and ceftaroline (MIC=0.50), but resistant to daptomycin (MIC=2). Vancomycin was initiated in view of documented drug allergy to ceftriaxone but repeated blood cultures showed the persistence of MSSA. Antibiotics were switched to linezolid for 3 days before switching to tedizolid due to previous neutropenia with linezolid. Blood cultures had documented clearance with tedizolid.
Discussion and Conclusion: In both our patients, tedizolid was introduced after a few days of vancomycin therapy. Hence, the efficacy of tedizolid as the first-line therapy for the treatment of staphylococcus bacteremia remains unknown. Nevertheless, in both patients, there was no relapse of staphylococcus bacteremia when tedizolid was used to complete the antibiotic therapy. The optimal treatment duration of staphylococcus bacteremia with tedizolid also remains unknown.
 
Publisher SCIENCEDOMAIN international
 
Date 2019-08-21
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
 
Identifier http://journalijmpcr.com/index.php/IJMPCR/article/view/30103
10.9734/ijmpcr/2019/v12i230103
 
Source International Journal of Medical and Pharmaceutical Case Reports; 2019 - Volume 12 [Issue 2]; 1-4
2394-109X
 
Language eng
 
Relation http://journalijmpcr.com/index.php/IJMPCR/article/view/30103/56480
http://journalijmpcr.com/index.php/IJMPCR/article/view/30103/56481
 
Rights Copyright (c) 2019 © 2019 Loo et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library